Researchers from MedImmune, a division of pharmaceutical company AstraZeneca, earlier this week presented their findings of a Phase II trial of anifrolumab, which is used to treat moderate to severe lupus.

The National Parkinson's Foundation (NPF) said Tuesday that Chicago and Tampa will become the newest sites for the Edmond J. Safra National Parkinson's Wellness Initiative.

These are the first guidelines for children who have been diagnosed with pulmonary hypertension.

The goal is to "create the medical school of the future."

Upon confirmation by the U.S. Senate, Dr. Califf will become the next FDA commissioner.

The drug can now be used in the treatment of HIV-1 infection in patients 12 and older.

The Centers for Medicare and Medicaid Services revealed this week what the premiums and deductibles for 2016 would be for patients using Medicare Part A (for inpatient hospital services) and Part B (for physician and outpatient hospital services).

A recent review by the U.S. Food and Drug Administration (FDA) shows that long-term use of the blood thinner Plavix (clopidogrel) has no effect on a patient's risk of death from heart disease.

I Am Essential, a coalition of 197 patient and community organizations, seeks to have the federal government better define and address discriminatory insurance plan practices.

Biotechnology company Astellas Pharma, Inc. said Monday it entered into an agreement for its subsidiary, Laurel Acquisition, Inc.,  to purchase Ocata Therapeutics, Inc. The goal of the deal is to bring the two companies' resources together to develop cutting-edge therapies for patients living with severe ophthalmic diseases.

The Lupus Foundation of America said Tuesday that a discussion of the positive results of a recent Phase II clinical study of Anifrolumab, a potential treatment for systemic lupus, is available on its website.

Researchers have uncovered information about amyotrophic lateral sclerosis (ALS), known as Lou Gehrig's disease, that could lead to major breakthroughs in the treatment of ALS and dementia.

To mark National Diabetes Month, the North Dakota Department of Health's (NDDoH) Diabetes Program and its partners are promoting lifestyle changes that, although seemingly small, could significantly improve the quality of life for the nearly one in 11 North Dakotans who are living with diabetes. Other ways to manage diabetes include eating meals and snacks that are healthy.

Tagrisso, a drug manufactured by pharmaceutical company Astra Zeneca that is taken orally to treat patients living with advanced non-small cell lung cancer (NSCLC), has been granted accelerated approval from the U.S. Food and Drug Administration (FDA).

Osimertinib (TAGRISSO), a once-daily tablet indicated for the treatment of specific lung cancers, has been granted accelerated approval by the U.S. Food and Drug Administration (FDA).

The American Medical Association (AMA) recently announced its partnership with MATTER, a health care technology organization in Chicago, to create the Interaction Studio, which brings together innovative health care technology startups, research universities and health care professionals.

A recent proposal by the U.S. Department of Housing and Urban Development (HUD) may cause all public housing properties to be smoke-free.

An order by the U.S. Food and Drug Administration (FDA) has recalled all of Custom Ultrasonics' automated endoscope reprocessors (AERs) from health care facilities.

Patients that are using Lifescan, Inc.'s OneTouch Reveal mobile app to help manage their diabetes are now able to view their blood sugar readings directly on their iPhones and, if they so choose, share those readings -- in a private and secure manner -- with various members of their health care teams.

The New York State Department of Health (NYSDOH) along with the Office for People with Developmental Disabilities (OPWDD) have announced that the two organizations are collaborating to test a new model that is aimed at providing enrollees in Medicare and Medicaid with care that is both more coordinated and personal.